Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SC-262 by Sana Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval
SC-262 is under clinical development by Sana Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...
SC-262 by Sana Biotechnology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
SC-262 is under clinical development by Sana Biotechnology and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
SC-262 by Sana Biotechnology for Follicular Lymphoma: Likelihood of Approval
SC-262 is under clinical development by Sana Biotechnology and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
SC-262 by Sana Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval
SC-262 is under clinical development by Sana Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
SC-262 by Sana Biotechnology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
SC-262 is under clinical development by Sana Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...